| Schedule of Disaggregation of Revenue |
The following table presents revenue from contracts with customers by product category and platform for the three and nine-month periods ended September 30, 2026 and 2025 (in thousands): | | | | | | | | | | | | | | | Three Months Ended | | Nine Months Ended | | | September 30, | | September 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Foundational | | | | | | | | | | | | | Access | | $ | 157,922 | | $ | 151,508 | | $ | 470,832 | | $ | 438,028 | OEM | | | 46,278 | | | 41,499 | | | 134,156 | | | 128,140 | Procedural Solutions | | | 27,162 | | | 32,287 | | | 81,599 | | | 92,597 | Vascular Intervention | | | 42,367 | | | 35,391 | | | 123,057 | | | 103,195 | Other | | | 2,006 | | | 221 | | | 2,531 | | | 1,710 | Total Foundational | | | 275,735 | | | 260,906 | | | 812,175 | | | 763,670 | | | | | | | | | | | | | | Therapeutic | | | | | | | | | | | | | Cardiac Therapies | | | 27,547 | | | 25,530 | | | 83,461 | | | 69,019 | Endoscopy | | | 23,428 | | | 17,631 | | | 68,767 | | | 52,582 | OEM | | | 13,089 | | | 9,953 | | | 33,365 | | | 30,830 | Oncology | | | 27,085 | | | 23,263 | | | 76,367 | | | 69,257 | Renal Therapies | | | 13,550 | | | 13,808 | | | 37,775 | | | 40,014 | Vascular Intervention | | | 35,810 | | | 33,066 | | | 105,054 | | | 96,598 | Total Therapeutic | | | 140,509 | | | 123,251 | | | 404,789 | | | 358,300 | | | | | | | | | | | | | | Total | | $ | 416,244 | | $ | 384,157 | | $ | 1,216,964 | | $ | 1,121,970 |
The following table presents revenue from contracts with customers by geographic region for the three and nine-month periods ended September 30, 2026 and 2025 (in thousands): | | | | | | | | | | | | | | | Three Months Ended | | Nine Months Ended | | | September 30, | | September 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Domestic | | $ | 255,946 | | $ | 230,597 | | $ | 734,513 | | $ | 671,243 | International | | | 160,298 | | | 153,560 | | | 482,451 | | | 450,727 | Total | | $ | 416,244 | | $ | 384,157 | | $ | 1,216,964 | | $ | 1,121,970 |
|